Vor Biopharma Inc (VOR)

$13.49 -0.66 (-4.66%)
Market Cap 147.32M
Revenue (ttm) 0.00
Net Income (ttm) -116.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,159,000
Avg Vol 2,061,964
Day's Range N/A - N/A
Shares Out 10.41M
Stochastic %K 74%
Beta 2.02
Analysts Strong Sell
Price Target $38.67

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
100 Cambridgepark Drive, Suite 101, Cambridge, United States
jreddyN
jreddyN Jan. 14 at 4:57 AM
$VOR https://www.vorbio.com/our-pipeline/
0 · Reply
SwamiGodu
SwamiGodu Jan. 13 at 7:05 PM
$VOR Well into 2028. Longest runway of any of the biotechs I'm invested in!
0 · Reply
Buyorsell4321
Buyorsell4321 Jan. 13 at 3:46 PM
$VOR Buy the dip. Ra Capital owns the company. 😃
0 · Reply
GSP
GSP Jan. 13 at 12:37 PM
$VOR may be setting up for a breakout soon. .
0 · Reply
GooRich
GooRich Jan. 13 at 9:11 AM
$VOR why calls not movent is this stock ?
0 · Reply
GSP
GSP Jan. 12 at 9:57 PM
$IREN $IMSR $NVTS $EVTV $VOR
0 · Reply
jreddyN
jreddyN Jan. 12 at 5:51 PM
$VOR On January 12, 2026, Vor Biopharma Inc. (the “Company”) released the Presentation (as defined below), which includes the following selected preliminary financial information for the fiscal year ended December 31, 2025: As of December 31, 2025, the Company’s cash, cash equivalents, and short-term investments were approximately $450 million. As previously announced, the company will be presenting and hosting one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PT Location: The Westin St. Francis, Georgian Room
0 · Reply
Focalalria
Focalalria Jan. 12 at 5:02 PM
$VOR https://ir.vorbio.com/static-files/d477e075-7f0f-46f3-afa3-a5facfb9252e
0 · Reply
dixiebull
dixiebull Jan. 12 at 4:07 PM
$VOR $CRML $APLD $IMSR $BW
1 · Reply
topstockalerts
topstockalerts Jan. 12 at 2:22 PM
$VOR strong watch at these levels
0 · Reply
Latest News on VOR
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 7 days ago

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Dec 23, 2025, 4:01 PM EST - 21 days ago

Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Vor Bio Announces $150 Million Private Placement

Dec 15, 2025, 8:00 AM EST - 4 weeks ago

Vor Bio Announces $150 Million Private Placement

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 2 months ago

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Nov 11, 2025, 9:43 AM EST - 2 months ago

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Nov 10, 2025, 9:56 PM EST - 2 months ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Nov 10, 2025, 4:01 PM EST - 2 months ago

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Nov 8, 2025, 11:45 AM EST - 2 months ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Vor Bio to Participate in Upcoming Investor Conferences

Nov 7, 2025, 8:00 AM EST - 2 months ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Nov 3, 2025, 8:00 AM EST - 2 months ago

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 31, 2025, 4:30 PM EDT - 2 months ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Oct 29, 2025, 11:01 AM EDT - 2 months ago

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Oct 22, 2025, 4:30 PM EDT - 2 months ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Oct 17, 2025, 8:00 AM EDT - 3 months ago

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Oct 16, 2025, 8:00 AM EDT - 3 months ago

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Oct 14, 2025, 8:00 AM EDT - 3 months ago

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Sep 29, 2025, 7:00 AM EDT - 3 months ago

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Sep 25, 2025, 11:48 AM EDT - 3 months ago

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Vor Bio Appoints Navid Z. Khan, Ph.D.

Sep 23, 2025, 8:00 AM EDT - 4 months ago

Vor Bio Appoints Navid Z. Khan, Ph.D.

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Sep 17, 2025, 9:00 PM EDT - 4 months ago

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Sep 17, 2025, 4:15 PM EDT - 4 months ago

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 12, 2025, 4:15 PM EDT - 4 months ago

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Aug 27, 2025, 8:00 AM EDT - 4 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Aug 13, 2025, 11:15 AM EDT - 5 months ago

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 13, 2025, 8:30 AM EDT - 5 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Aug 4, 2025, 8:30 AM EDT - 5 months ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 21, 2025, 8:30 AM EDT - 6 months ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 18, 2025, 4:00 PM EDT - 6 months ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 17, 2025, 8:30 AM EDT - 6 months ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 10, 2025, 4:00 PM EDT - 6 months ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:00 PM EDT - 7 months ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 30, 2025, 2:31 PM EDT - 7 months ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 7 months ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Jun 25, 2025, 4:45 PM EDT - 7 months ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025, 8:30 AM EDT - 8 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 4:05 PM EDT - 10 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 13, 2025, 8:00 AM EST - 11 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Jan 8, 2025, 9:00 AM EST - 1 year ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 1 year ago

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Dec 9, 2024, 7:30 AM EST - 1 year ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 6, 2024, 9:35 AM EDT - 1 year ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Sep 5, 2024, 4:01 PM EDT - 1 year ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 2 years ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

jreddyN
jreddyN Jan. 14 at 4:57 AM
$VOR https://www.vorbio.com/our-pipeline/
0 · Reply
SwamiGodu
SwamiGodu Jan. 13 at 7:05 PM
$VOR Well into 2028. Longest runway of any of the biotechs I'm invested in!
0 · Reply
Buyorsell4321
Buyorsell4321 Jan. 13 at 3:46 PM
$VOR Buy the dip. Ra Capital owns the company. 😃
0 · Reply
GSP
GSP Jan. 13 at 12:37 PM
$VOR may be setting up for a breakout soon. .
0 · Reply
GooRich
GooRich Jan. 13 at 9:11 AM
$VOR why calls not movent is this stock ?
0 · Reply
GSP
GSP Jan. 12 at 9:57 PM
$IREN $IMSR $NVTS $EVTV $VOR
0 · Reply
jreddyN
jreddyN Jan. 12 at 5:51 PM
$VOR On January 12, 2026, Vor Biopharma Inc. (the “Company”) released the Presentation (as defined below), which includes the following selected preliminary financial information for the fiscal year ended December 31, 2025: As of December 31, 2025, the Company’s cash, cash equivalents, and short-term investments were approximately $450 million. As previously announced, the company will be presenting and hosting one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PT Location: The Westin St. Francis, Georgian Room
0 · Reply
Focalalria
Focalalria Jan. 12 at 5:02 PM
$VOR https://ir.vorbio.com/static-files/d477e075-7f0f-46f3-afa3-a5facfb9252e
0 · Reply
dixiebull
dixiebull Jan. 12 at 4:07 PM
$VOR $CRML $APLD $IMSR $BW
1 · Reply
topstockalerts
topstockalerts Jan. 12 at 2:22 PM
$VOR strong watch at these levels
0 · Reply
LIVE_Trading
LIVE_Trading Jan. 12 at 1:58 PM
$VOR getting ready
0 · Reply
LIVE_Trading
LIVE_Trading Jan. 12 at 1:45 PM
$VOR here 14.63-70
0 · Reply
GSP
GSP Jan. 12 at 1:41 PM
Updated gapper list for today (con't): $EVTV $DAWN $STKL $VOR $RDW .
1 · Reply
GSP
GSP Jan. 12 at 1:26 PM
$VOR moving in pre-market.
1 · Reply
kellyc09
kellyc09 Jan. 12 at 1:23 PM
$VOR Up over $14 pre market and not seeing any new news. It has had this pattern before and sold off but would love to see this hold. Might be a good bio tech day .
0 · Reply
jreddyN
jreddyN Jan. 10 at 4:03 PM
$VOR Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PT Location: The Westin St. Francis, Georgian Room A live webcast and archived replay of the presentation will be available on the Company’s website at: https://ir.vorbio.com/events-presentations/
0 · Reply
SylvanEmperor
SylvanEmperor Jan. 10 at 8:40 AM
$VOR hrmm. Is this not showing up correctly in anyone's trading platform?
0 · Reply
HahaYouSUCK
HahaYouSUCK Jan. 10 at 3:40 AM
$VOR study terminated? https://clinicaltrials.gov/study/NCT05306574
3 · Reply
Ralphbeach
Ralphbeach Jan. 9 at 10:42 PM
$VOR You have the three musketeers on this, JPM, Citi and Cowen. Back the truck up.
1 · Reply
hegdaom
hegdaom Jan. 9 at 1:42 PM
$VOR
0 · Reply
SnoopDawg
SnoopDawg Jan. 9 at 12:50 PM
$VOR Citigroup initiates w buy and $50 target.
1 · Reply
hegdaom
hegdaom Jan. 9 at 11:28 AM
$VOR Pre market its running. any PR?
0 · Reply